Carbapenem-resistant Enterobacteriaceae: Prevalence and risk factors in a single community-based hospital in Korea

Infection and Chemotherapy

Volumn 48, Issue 3, 2016, Pages 166-173

  Lee, Hyo Jin ^a   Choi, Jae Ki ^a   Cho, Sung Yeon ^a   Kim, Si Hyun ^a   Park, Sun Hee ^a   Choi, Su Mi ^a   Lee, Dong Gun ^a   Choi, Jung Hyun ^a   Yoo, Jin Hong ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Carbapenems; Drug resistance; Enterobacteriaceae; Prevalence; Risk factors

Indexed keywords

AMIKACIN; AZTREONAM; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; HYPERTENSIVE FACTOR; TIGECYCLINE;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CHARLSON COMORBIDITY INDEX; CITROBACTER FREUNDII; COMMUNITY HOSPITAL; CONSCIOUSNESS LEVEL; CONTROLLED STUDY; DEMOGRAPHY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; HUMAN; INTENSIVE CARE; INTRAVASCULAR CATHETER; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MORGANELLA MORGANII; NONHUMAN; PREVALENCE; PROTEUS MIRABILIS; PROVIDENCIA RETTGERI; RETROSPECTIVE STUDY; RISK FACTOR; SERRATIA MARCESCENS; SOUTH KOREA;

EID: 84992193935     PISSN: 20932340     EISSN: 20926448     Source Type: Journal    
DOI: 10.3947/ic.2016.48.3.166     Document Type: Article

References (34)

1. Wang JT, Wu UI, Lauderdale TL, Chen MC, Li SY, Hsu LY, Chang SC. Carbapenem-nonsusceptible Enterobacteriaceae in Taiwan. PLoS One 2015;10:e0121668.
2. Kaniga K, Flamm R, Tong SY, Lee M, Friedland I, Redman R. Worldwide experience with the use of doripenem against extended-spectrum-β-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. Antimicrob Agents Chemother 2010;54:2119-24.
3. Ling ML, Tee YM, Tan SG, Amin IM, How KB, Tan KY, Lee LC. Risk factors for acquisition of carbapenem resistant Enterobacteriaceae in an acute tertiary care hospital in Singapore. Antimicrob Resist Infect Control 2015;4:26.
4. Xu Y, Gu B, Huang M, Liu H, Xu T, Xia W, Wang T. Epidemiology of carbapenem resistant Enterobacteriaceae (CRE) during 2000-2012 in Asia. J Thorac Dis 2015;7:376-85.
5. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008;52:1028-33.
6. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:1099-106.
7. Patel N, Harrington S, Dihmess A, Woo B, Masoud R, Martis P, Fiorenza M, Graffunder E, Evans A, McNutt LA, Lodise TP. Clinical epidemiology of carbapenem-intermediate or-resistant Enterobacteriaceae. J Antimicrob Chemother 2011;66:1600-8.
8. Lee K, Lee HS, Jang SJ, Park AJ, Lee MH, Song WK, Chong Y; Members of Korean Nationwide Surveillance ofAntimicrobial Resistance Group. Antimicrobial resistance surveillance of bacteria in 1999 in Korea with a special reference to resistance of enterococci to vancomycin and gram-negative bacilli to third generation cephalosporin, imipenem, and fluoroquinolone. J Korean Med Sci 2001;16:262-70.
9. Kwak YG, Choi SH, Choo EJ, Chung JW, Jeong JY, Kim NJ, Woo JH, Ryu J, Kim YS. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist 2005;11:165-9.
10. Lee H, Ko KS, Song JH, Peck KR. Antimicrobial activity of doripenem and other carbapenems against gram-negative pathogens from Korea. Microb Drug Resist 2011;17:37-45.
11. Gómez Rueda V, Zuleta Tobón JJ. Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae: a casecase-control study. Colomb Med (Cali) 2014;45:54-60.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
13. Kim J, Lee JY, Kim SI, Song W, Kim JS, Jung S, Yu JK, Park KG, Park YJ. Rates of fecal transmission of extended-spectrum β-lactamase-producing and carbapenem-resistant Enterobacteriaceae among patients in intensive care units in Korea. Ann Lab Med 2014;34:20-5.
14. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: Twenty-second informational supplement M100-S22. CLSI: Wayne, PA; 2012.
15. Chang YY, Chuang YC, Siu LK, Wu TL, Lin JC, Lu PL, Wang JT, Wang LS, Lin YT, Huang LJ, Fung CP. Clinical features of patients with carbapenem nonsusceptible Klebsiella pneumoniae and Escherichia coli in intensive care units: a nationwide multicenter study in Taiwan. J Microbiol Immunol Infect 2015;48:219-25.
16. Logan LK, Renschler JP, Gandra S, Weinstein RA, Laxminarayan R; Centers for Disease Control; Prevention Epicenters Program. Carbapenem-resistant Enterobacteriaceae in children, United States, 1999-2012. Emerg Infect Dis 2015;21:2014-21.
17. Anderson KF, Lonsway DR, Rasheed JK, Biddle J, Jensen B, McDougal LK, Carey RB, Thompson A, Stocker S, Limbago B, Patel JB. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol 2007;45:2723-5.
18. Ampaire LM, Katawera V, Nyehangane D, Boum Y, Bazira J. Epidemiology of carbapenem resistance among multidrug resistant enterobacteriaceae in Uganda. Br Microbiol Res J 2015;8:418-23.
19. Torres-Gonzalez P, Cervera-Hernandez ME, Niembro-Ortega MD, Leal-Vega F, Cruz-Hervert LP, García-García L, Galindo-Fraga A, Martinez-Gamboa A, Bobadilla-Del Valle M, Sifuentes-Osornio J, Ponce-de-Leon A. Factors associated to prevalence and incidence of carbapenem-resistant Enterobacteriaceae fecal carriage: a cohort study in a Mexican Tertiary Care Hospital. PLoS One 2015;10:e0139883.
20. Guh AY, Bulens SN, Mu Y, Jacob JT, Reno J, Scott J, Wilson LE, Vaeth E, Lynfield R, Shaw KM, Vagnone PM, Bamberg WM, Janelle SJ, Dumyati G, Concannon C, Beldavs Z, Cunningham M, Cassidy PM, Phipps EC, Kenslow N, Travis T, Lonsway D, Rasheed JK, Limbago BM, Kallen AJ. Epidemiology of carbapenem-resistant enterobacteriaceae in 7 US communities, 2012-2013. JAMA 2015;314:1479-87.
21. Huh K, Kim J, Cho SY, Ha YE, Joo EJ, Kang CI, Chung DR, Lee NY, Song JH, Peck KR; Korean Network for Study on-Infectious Diseases (KONSID). Continuous increase of the antimicrobial resistance among gram-negative pathogens causing bacteremia: a nationwide surveillance study by the Korean Network for Study on Infectious Diseases (KONSID). Diagn Microbiol Infect Dis 2013;76:477-82.
22. Kim BM, Jeon EJ, Jang JY, Chung JW, Park J, Choi JC, Shin JW, Park IW, Choi BW, Kim JY. Four year trend of carbapenem-resistance in newly opened ICUs of a university-affiliated hospital of South Korea. Tuberc Respir Dis (Seoul) 2012;72:360-6.
23. Kim DK, Kim HS, Pinto N, Jeon J, D'Souza R, Kim MS, Choi JY, Yong D, Jeong SH, Lee K. Xpert CARBA-R assay for the detection of carbapenemase-producing organisms in in-tensive care unit patients of a Korean Tertiary Care Hospital. Ann Lab Med 2016;36:162-5.
24. Thaden JT, Pogue JM, Kaye KS. Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence 2016:6;1-14.
25. Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN. Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013). Diagn Microbiol Infect Dis 2015;83:183-6.
26. Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011;37:415-9.
27. Kim SY, Shin J, Shin SY, Ko KS. Characteristics of carbapenem-resistant Enterobacteriaceae isolates from Korea. Diagn Microbiol Infect Dis 2013;76:486-90.
28. Jiao Y, Qin Y, Liu J, Li Q, Dong Y, Shang Y, Huang Y, Liu R. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization and predictors of mortality: a retrospective study. Pathog Glob Health 2015;109:68-74.
29. Giannella M, Trecarichi EM, De Rosa FG, Del Bono V, Bassetti M, Lewis RE, Losito AR, Corcione S, Saffioti C, Bartoletti M, Maiuro G, Cardellino CS, Tedeschi S, Cauda R, Viscoli C, Viale P, Tumbarello M. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. Clin Microbiol Infect 2014;20:1357-62.
30. Correa L, Martino MD, Siqueira I, Pasternak J, Gales AC, Silva CV, Camargo TZ, Scherer PF, Marra AR. A hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection. BMC Infect Dis 2013;13:80.
31. Ahn JY, Song JE, Kim MH, Choi H, Kim JK, Ann HW, Kim JH, Jeon Y, Jeong SJ, Kim SB, Ku NS, Han SH, Song YG, Yong D, Lee K, Kim JM, Choi JY. Risk factors for the acquisition of carbapenem-resistant Escherichia coli at a tertiary care center in South Korea: a matched case-control study. Am J Infect Control 2014;42:621-5.
32. Jeon MH, Choi SH, Kwak YG, Chung JW, Lee SO, Jeong JY, Woo JH, Kim YS. Risk factors for the acquisition of carbapenem-resistant Escherichia coli among hospitalized patients. Diagn Microbiol Infect Dis 2008;62:402-6.
33. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011;53:60-7.
34. Martirosov DM, Lodise TP. Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae. Diagn Microbiol Infect Dis 2016;85:266-75.